Use the hyperlinks, where available to access additional clinical trial information.
A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor
Eligible patients will receive induction therapy with oral lorlatinib, every day for 12 weeks. Participants will then move onto the alternating phase of the trial, in which patients will receive crizotinib for 4 weeks, then lorlatinib for 8 weeks, then crizotinib for another 4 weeks, and lorlatinib for 8 weeks until disease progression or unacceptable side effects are experienced/observed. Following progression, some participants may be eligible to continue with alternating treatment or switch to continuous treatment until further progression, depending on the potential clinical benefit.